Proton-pump inhibitor (PPI), gastric antisecretory agent Used for treatment of duodenal and gastric ulcers, erosive esophagitis, GERD, heartburn, ZE syndrome, and NSAID-induced ulcers; combined with antibiotics for eradication of H. pylori Associated with increased risk of Clostridium difficile-associated diarrhea.

Composition

Each capsule contains enteric coated pellets of Lansoprazole equivalent to Lansoprazole 15mg. (USP Specs)

Indication

SOPRAZON is used: For the short-term treatment of frequent dyspepsia or pyrosis (heartburn) that occurs 2 or more times per week. For the treatment of non-erosive gastroesophageal reflux disease (GERD). For the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. For Helicobacter pylori (H. pylori) eradication. For the treatment of active duodenal ulcer. For the treatment of active benign gastric ulcer. For the treatment of erosive esophagitis (erosive GERD). For NSAID-induced ulcer prophylaxis or healing. For stress gastritis prophylaxis in critically-ill patients. For the treatment of proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) in the differential diagnosis of eosinophilic esophagitis (EoE).